RxDoctor Payments Data

Joseph Levine, MD

Hematology & Oncology · Duluth, MNNPI 1801074182

Payments from drug & device makers

$516in general payments, 2019–2025

Across 11 payments — averaging $46.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Monteris Medical Corporation$139
  • Intuitive Surgical$131
  • AstraZeneca$112
  • Astellas Pharma US Inc$31
  • Pfizer$26
  • Novocure Inc.$22
  • plus $54 from 4 others

What the payments were for

  • Food & beverage$35569%
  • Education$16131%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$516 in reported general payments places this provider in the 40th percentile of 193 hematology & oncology providers in Minnesota.

See all hematology & oncology providers in Minnesota

Medicare billing

Part B allowed, 2024
$26,374
Medicare patients
135
Services billed
428

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ImbruvicaIbrutinib58$734,223
IbrancePalbociclib23$360,136
Lenalidomide20$258,326
TagrissoOsimertinib Mesylate12$190,597
VerzenioAbemaciclib11$159,295
CalquenceAcalabrutinib Maleate17$135,566
VenclextaVenetoclax11$134,058
BesremiRopeginterferon Alfa-2b-Njft15$126,751
EliquisApixaban68$59,886
Erlotinib Hcl14$45,110
Abiraterone Acetate124$41,519
Hydroxyurea116$2,763
Imatinib Mesylate22$1,753
Anastrozole78$1,527
Dexamethasone76$1,431

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance, Eliquis$26$420,02191 claims
AstraZenecaTagrisso, Calquence$112$326,16329 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 193 hematology & oncology providers in Minnesota.

Other hematology & oncology in Duluth

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →